UPLC-MS/MS assay validation for tacrolimus quantitative determination in peripheral blood T CD4+and B CD19+lymphocytes

Imagem de Miniatura
Arquivos
art_ROMANO_UPLCMSMS_assay_validation_for_tacrolimus_quantitative_determination_in_2018.PDF (1.88 MB)
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
OLIVEIRA, Nayara Duarte de
OKUDA, Larissa Mitsue
Citação
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, v.152, p.306-314, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Monitoring tacrolimus (Tac) exposure in cell matrices enriched with lymphocytes can improve Tac therapeutic drug monitoring (TDM) in solid organ transplant recipients. An UPLC-MS/MS based assay for Tac quantification in peripheral blood T CD4+ and B CD19+ lymphocytes was developed. Peripheral blood mononuclear cells (PBMC) were obtained by density gradient centrifugation and highly purified (purity >90%) T CD4+ and B CD19+ cell suspensions were acquired by magnetic negative selection from whole blood of 6 healthy volunteers. The purity of lymphocyte suspensions was checked by flow cytometry. Tac extraction was performed in a liquid-liquid zinc sulfate, methanol and acetonitrile based medium. Ascomycin was used as internal standard. The equipment used was a Waters (R) Acquity (TM) UPLC system (Waters Corporation, Milford, MA, USA). The chromatographic run was performed on a Waters (R) MassTrak TDM C18 (2.1 x 10 mm) column (Waters Corporation, Milford, MA, USA). at a flow rate of 0.4 mL/min. The instrument was set in electrospray positive ionization mode. The method was validated according to Clinical Laboratory Standard Institute (CLSI) guidelines and showed a high sensitivity and specificity over a range of 0-5.2 ng/mL in PBMC, 0-5.0 ng/mL in T CD4+ Lymphocytes and 0-5.3 ng/mL in B CD19+ lymphocytes. Precision was appropriate with CV of intra-assay quantifications ranging from 4.9 to 7.4%, and of inter-assay quantifications from 7.2 to 13.9%. Limit of detection and quantification were 0.100 and 0.115 ng/mL in PBMC, 0.058 and 0.109 ng/mL in T CD4+ and 0.017 and 0.150 ng/mL in B CD19+ cells. Matrix effect was not significant among all the studied matrices. Samples showed stability for Tac quantification over a period of 90 days either at room temperature or at -30 degrees C storage conditions. The method was applied to clinical samples of 20 kidney transplant recipients. Concentrations ranged from 2.200 to 11.900 ng/mL in whole blood, from 0.005 to 0.570 ng/10(6) cells in PBMC, from 0.081 to 1.432 ng/10(6) cells in T CD4+, and from 0.197 to 1.564 ng/10(6) cells in B CD19+ cell matrices. The method has potential applicability for Tac TDM in solid organ transplant recipients.
Palavras-chave
Tacrolimus, T lymphocytes, B lymphocytes, Flow cytometry, Mass spectrometry
URI
https://observatorio.fm.usp.br/handle/OPI/26471
Referências
  1. Bouamar R, 2013, AM J TRANSPLANT, V13, P1253, DOI 10.1111/ajt.12191
  2. Capron A, 2012, TRANSPL INT, V25, P41, DOI 10.1111/j.1432-2277.2011.01365.x
  3. Capron A, 2010, PHARMACOGENOMICS, V11, P703, DOI 10.2217/PGS.10.43
  4. Capron A, 2009, THER DRUG MONIT, V31, P178, DOI 10.1097/FTD.0b013e3181905aaa
  5. CLSI Mass Spectrometry in the Clinical Laboratory: General Principle and Guidance, Approved Guideline, 2007, C50A CLSI, V27
  6. CLSI Evaluation of the Linearity of Quantitative Measurement Procedures: a Statistical Approach, Approved Guideline, 2003, EP06A CLSI, V23
  7. CLSI Evaluation of Precision Performance of Quantitative Measurement Methods, 2004, EP5A2 CLSI, V24
  8. COON JS, 1991, HUM IMMUNOL, V32, P134, DOI 10.1016/0198-8859(91)90110-U
  9. Crettol S, 2008, PHARMACOGENET GENOM, V18, P307, DOI 10.1097/FPC.0b013e3282f7046f
  10. Donnenberg VS, 2004, TRANSPLANTATION, V77, P1699, DOI 10.1097/01.TP.0000131163.43015.85
  11. Falck P, 2008, TRANSPLANTATION, V85, P179, DOI 10.1097/TP.0b013e31815feede
  12. Falck P, 2007, J CHROMATOGR B, V852, P345, DOI 10.1016/j.jchromb.2007.01.039
  13. Ford J, 2003, J IMMUNOL METHODS, V274, P129, DOI 10.1016/S0022-1759(02)00509-4
  14. Grievink HW, 2016, BIOPRESERV BIOBANK, V14, P410, DOI 10.1089/bio.2015.0104
  15. JUSKO WJ, 1995, THER DRUG MONIT, V17, P606, DOI 10.1097/00007691-199512000-00011
  16. Lemaitre F, 2013, CLIN BIOCHEM, V46, P1538, DOI 10.1016/j.clinbiochem.2013.02.011
  17. Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0
  18. Zahir H, 2004, THER DRUG MONIT, V26, P506, DOI 10.1097/00007691-200410000-00008
  19. Zahir H, 2001, J PHARMACOL TOXICOL, V46, P27, DOI 10.1016/S1056-8719(02)00158-2

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/19